Coronavirus Disease (COvid-)19 REgistry on THROMBOSIS Complications

COvid-19 REgistry on THROMBOSIS Complications Associated With Hospitalization

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04780295

Acronym

CORE-THROMB

Enrollment

2708

Registered

2021-03-03

Start date

2020-04-15

Completion date

2021-05-18

Last updated

2023-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Covid19, thromboembolism, thromboprophylaxis, pulmonary embolism, anticoagulation

Brief summary

This online-based, observational retrospective registry aims to (i) study the rate of cardiovascular events, encompassing venous thromboembolic and arterial events, in consecutive hospitalized patients with coronavirus (Covid19), (ii) investigate the prevalent use of thromboprophylaxis, (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with Covid19. This will also facilitate and constitute the basis for the conduction of interventional thromboprophylaxis studies in patients with Covid19.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Hospitalized patients aged ≥ 18 years with a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV2)

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame	Description
Fatal or non-fatal venous thromboembolism (VTE)	during index hospitalization for Covid19	Rate of thromboembolic events encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT)
Fatal or non-fatal cardiovascular events	during index hospitalization for Covid19	Rate of cardiovascular events encompassing stroke and myocardial infarction
All-cause death	during index hospitalization for Covid19	Rate of death from any cause

Secondary

Measure	Time frame	Description
In-hospital course of D-dimer (μg/mL)	during index hospitalization for Covid19	Course of laboratory biomarker
Prevalence of cardiovascular risk factors	at baseline/enrollment	Baseline prevalence of cardiovascular risk factors and use of specific medications (statins, Angiotensin-converting enzyme \[ACE\] inhibitors)
In-hospital course of Troponin (ng/ml)	during index hospitalization for Covid19	Course of laboratory biomarker
Length of hospitalization	first index hospitalization for Covid19	Duration of inpatient stay
Prevalent use of in-hospital thromboprophylaxis	during index hospitalization for Covid19	Use of unfractionated heparin (UFH), low-molecular weight heparin (LMWH), or direct oral anticoagulants (DOAC) on/after admission due to Covid19

Countries

Brazil, Denmark, Germany, Ireland, Italy, Mexico, Spain, Turkey (Türkiye)

Outcome results